1st Quarter - Report

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Coronavirus funding and response legislation

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS)

Copyright/Patent/Trademark CPT

Address concerns with provisions of patent litigation reform, including inter partes review. Support STRONGER Patents Act. Oppose "march-in" rights and "compulsory licensing" proposals.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Health Issues HCR

Support FDA user fee programs and review process consistency and predictability. Support policy improvements to address antimicrobial resistance.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

Support NIH research funding. Support implementation of 21st Century Cures Act.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS)

Trade (domestic/foreign) TRD

Support data exclusivity provisions in USMCA / Oppose proposals to reduce data exclusivity.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System Support reforms to enable Value Based Healthcare, including reforms to Anti-Kickback Statute & Stark Law Oppose International Pricing Index/reference pricing in Medicare Support Ensuring Patient Access to/coverage of critical breakthrough products via Hospital Inpatient Prospective Payment System (IPPS) proposed and final rules, Hospital Outpatient Prospective Patient System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed and final rules, and legislation Oppose drug importation proposals

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Budget/Appropriations BUD

Labor/HHS/Ed Appropriations: NIH, antimicrobial resistance, biodefense/pandemic, CDC, science/math education, and strategic stockpile funding and preparation; Coronavirus funding and response; FDA Appropriations; PTO Appropriations.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
MOLLY FISHMAN —

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.